-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Amicus Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q1 2024.
- Amicus Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $0.000.
- Amicus Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$4.94M, a 54978% decline from 2022.
- Amicus Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $9K, a 73.5% decline from 2021.
- Amicus Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $34K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)